Navigation Links
Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
Date:1/8/2009

SOUTH SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today provided an overview of its 2009 clinical goals for development of picoplatin, its lead product candidate. Picoplatin is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. It is currently being evaluated in a Phase 3 registrational trial (SPEAR or Study of Picoplatin Efficacy After Relapse) in small cell lung cancer (SCLC), and in Phase 2 clinical trials as a first-line chemotherapy in colorectal cancer (CRC) and hormone-refractory (HRPC) or castration-resistant (CRPC) prostate cancer. Picoplatin is designed to overcome platinum resistance and has the potential for an improved safety profile compared to other platinum-based chemotherapies currently in use.

"We expect that 2009 will be a catalytic year for Poniard, as we expect to complete enrollment in our ongoing registration trial in small cell lung cancer. We believe the results of this trial could support an NDA filing, leading to approval and commercialization of picoplatin in 2010," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We continue to execute our clinical strategy to broaden picoplatin's potential as a platform product. We plan to present clinical data from our other ongoing Phase 2 colorectal and prostate cancer trials at multiple medical conferences. These data, together with picoplatin data in over 750 patients in a broad range of tumor types supports future development and use of picoplatin for the treatment of lung, colorectal, ovarian, prostate, breast, head and neck, bladder, pancreatic and other cancers."

"Poniard is fortunate to have sufficient
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Announces Upcoming Conference Participation
4. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
5. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
6. MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
7. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
8. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
9. Akrimax Pharmaceuticals Announces Manufacturing Partnership
10. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... of Medicine at the University of Pennsylvania in collaboration ... $8 million grant from the National Cancer Institute (NCI) ... in patients with malignant pleural mesothelioma, a rare, aggressive ... the lining of the lungs and is caused almost ... a clinical trial and additional studies looking at the ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... groundbreaking program,dealing with the deteriorating physical, mental and ... gender specific psychological and,medical needs will take place ... under the auspices of members of the Westchester,medical ... J. Legato,M.D. and Lionel Tiger, Ph.D., Dr. ...
... Experts develop sequence of instructions they say could help doctors ... safety experts say that almost all kids who are allergic ... set of standard precautions. , Reporting in the September ... by the Johns Hopkins Children,s Center put forth a step-by-step ...
... Martin Schiff, M.D.,is an illustrious member and recognized authority ... career is detailed in "Who,s Who in,California," "Who,s Who ... in,the World," "Who,s Who in Medicine and Health Care" ... to devote his expertise to exposing the,inaccurate, misleading theories ...
... Coast states are open, CVS/pharmacy will also donate water, ice, diapers and ... communities impacted by Hurricane Gustav, ... in Louisiana have re-opened since Hurricane Gustav,in the following cities and towns:, ... City Broussard Covington Cutoff Destrehan Franklinton ...
... 4 In some countries, lime juice is,thought to ... Against such a backdrop of misinformation and stigma, ... killed tens of millions,of people?, Part of the ... news media, says,Internews Network, an international media development nonprofit ...
... SAFC Pharma(TM), a focus,area within SAFC(R) ( ... SIAL ), today officially announced details,of a ... facility,designed to significantly increase its capacity to produce ... investment,includes the purchase of 15 acres of green ...
Cached Medicine News:Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2Health News:CVS/pharmacy Re-Opens 64 Stores in Louisiana 2Health News:More than 1,000 Journalists Enlisted in Fight Against HIV/AIDS 2Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 2Health News:SAFC Pharma(TM) Commits to Major Expansion of High Potency API Production at Madison Site 3
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Oct. 16 AngioGenex Inc. (OTC,Bulletin Board: AGGX.OB) ... molecules that are potent inhibitors of the Id ... filing of this patent,constitute major milestones in the ... Dr. Richard Salvador, President and CEO, and the,former ...
... Oct. 16 When eighty-six-year-old,Keith Hora went to see ... University of Newcastle in Australia, he was told he ... been diagnosed with stage III melanoma, one,of the most ... had multiple melanoma reoccurrences in the previously treated,area of ...
Cached Medicine Technology:AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
... over 20 years of experience in ... the Life Sciences, the Freedom EVO ... possibilities for expansion according to future ... software, Freedom EVOware, each system is ...
... EVO Clinical is an open platform for clinical ... in deck sizes of 75, 100, 150 ... instrument for your laboratory space and throughput requirements. ... features to allow new applications and to evolve ...
... liquid handling system that ... of up to three ... the same worksurface. Offered ... solutions for targeted applications ...
... The AccelNet Laboratory Automation Network ... clinical chemistry systems, an automated sample ... manager to create a single, powerful ... ideal for laboratories that need a ...
Medicine Products: